Top in GI: PPIs and eosinophilic esophagitis, tradipitant in gastroparesis

Real-world data have shown that patients with eosinophilic esophagitis achieved remission after receiving treatment with proton pump inhibitors. It was the top story in gastroenterology last week.

Another top story was about a study that showed tradipitant was associated with improvements in nausea and vomiting in patients with gastroparesis.

Read these and more top stories in gastroenterology below:

Real-world data show efficacy of PPIs in EoE

Patients with eosinophilic esophagitis achieved clinical and histological remission after undergoing treatment with proton pump inhibitors, according to study results. Read more.

Tradipitant improves nausea, vomiting in gastroparesis

Tradipitant correlated with statistically and clinically meaningful improvements in nausea and decreased vomiting in patients with idiopathic or diabetic gastroparesis, according to results from Gastroenterology. Read more.

Low incidence of SARs-CoV-2 among IBD patients on biologic therapy

Investigators found a low incidence of SARs-CoV-2 among patients with inflammatory bowel disease who were taking biologic therapy, according to recently published data in the Journal of Gastroenterology and Hepatology. Read more.

Self-expandable metal stents safe for pancreatic duct strictures in chronic pancreatitis

Fully covered self-expandable metal stents were safe and effective for treating main pancreatic duct strictures linked to symptomatic chronic pancreatitis, according to a study published in the Journal of Gastroenterology and Hepatology. Read more.

Endoscopic screening for gastric cancer cost-effective for Asian Americans in the U.S.

Endoscopic screening for gastric cancer with surveillance of gastric preneoplasia was cost-effective for Asian Americans aged at least 50 years, according to study results. Read more.